A retrospective study to evaluate the toxicity driven conversion from calcineurin inhibitor or TOR inhibitor to belatacept in kidney transplant recipients.
Phase of Trial: Phase IV
Latest Information Update: 03 May 2017
At a glance
- Drugs Belatacept (Primary) ; Sirolimus; Tacrolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 03 May 2017 Results presented at the 2017 American Transplant Congress.
- 20 Aug 2015 New trial record